Cannabidiol and Digoxin Interaction
Drug interaction information between Cannabidiol and Digoxin.
Cannabidiol and Digoxin have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Cannabidiol and Digoxin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Cannabidiol can block a protein that helps remove digoxin from your body, causing the drug to build up to higher levels.
What To Do
Your doctor should monitor your blood levels of digoxin closely to make sure they stay in a safe range.
FDA Label Information
Increases in exposure of other orally administered P‑gp substrates (e.g., sirolimus, tacrolimus, digoxin) may be observed when concomitantly used with EPIDIOLEX.
Cannabidiol Also Interacts With
- Clobazam moderate
- Clopidogrel minor
- Tizanidine minor
- Valproate minor
- Rifampin minor
Digoxin Also Interacts With
- Nicardipine major
- Posaconazole major
- Sotalol moderate
- Dofetilide moderate
- Ivabradine moderate
Frequently Asked Questions
Can I take Cannabidiol and Digoxin together?
This is a minor interaction. Your doctor should monitor your blood levels of digoxin closely to make sure they stay in a safe range.
How serious is the interaction between Cannabidiol and Digoxin?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Cannabidiol and Digoxin interact?
Cannabidiol can block a protein that helps remove digoxin from your body, causing the drug to build up to higher levels.
Understanding the Cannabidiol and Digoxin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Cannabidiol belongs to the Cannabinoid (Anticonvulsant) class and Digoxin belongs to the Cardiac Glycoside class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Cannabidiol can block a protein that helps remove digoxin from your body, causing the drug to build up to higher levels. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Cannabidiol has 8 total documented interactions on file in this dataset, and Digoxin has 120. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor your blood levels of digoxin closely to make sure they stay in a safe range. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Cannabidiol or Digoxin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.